[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
EMA has announced a meeting on December 8, 2016 to hear what drug developers and other groups have to say about its adaptive pathways program. The workshop agenda will an opportunity to discuss the lessons of the two-year pilot program and figure out the future of the staged approach to drug approvals. [For more on the adaptive pathways program and how it compares to EMA’s Priority Medicines (PRIME) approach for accelerating product development and review, see IPQ September 9, 2016.]
[/membership]
INTERNATIONAL PHARMACEUTICAL QUALITY
Inside the Global Regulatory Dialogue
